SavedAdd your journal

Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2016 / Cilt: 26 - Sayı: 3

Bilateral Sixth Nerve Palsies Possibly Associated with Arsenic Trioxide in Acute Promyelocytic Leukaemia

Pusem PATIR
Merve OYTUN
Ahmet A OZLUK
Güray SAYDAM
Ayhan DÖNMEZ
MURAT TOMBULOĞLU
Pages
176–178
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

PATIR, P., OYTUN, M., OZLUK, A. A., SAYDAM, G., DÖNMEZ, A., TOMBULOĞLU, M. (2016). Bilateral Sixth Nerve Palsies Possibly Associated with Arsenic Trioxide in Acute Promyelocytic Leukaemia. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 26 - Sayı: 3, 176–178. https://ajindex.com/articles/322840

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias: French-American-Brit- ish (FAB) co-operative group. Br J Haematol 33: 451-458, 1976.
  2. Bennett JM, Catovsky D, Daniel MT, et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 44: 169-170, 1980.
  3. Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79: 543- 553, 1992.
  4. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leu- kaemia. Lancet 1: 549-550, 1997.
  5. Grignani F, Ferrucci PF, Testa U, et al. The acute promyelo- cytic leukemia-specific PML-RAR alpha fusion protein inhib- its differentiation and promotes survival of myeloid precursor cells. Cell 74: 423-431, 1993.
  6. Tallman MS, Altman JK. Curative strategies in acute promye- locytic leukemia. Hematology Am Soc Hematol Educ Program 1: 391-399, 2008.
  7. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 120: 1570-1580, 2012.
  8. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and ar- senic trioxide for acute promyelocytic leukemia. N Engl J Med 369: 111-121, 2013.
  9. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all trans retinoic acid, arsenic tri- oxide, and gemtuzumab ozogamicin. J Clin Oncol 27: 504- 510, 2009.
  10. Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M.D. Anderson experience. Cancer 97: 2218- 2224, 2003.
  11. Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide ther- apy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 16: 617-622, 2002.
  12. Thery JC, Jardin F, Massy N, et al. Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treat- ment. Leuk Lymphoma 49: 168-170, 2008.
  13. Vahidnia A, Romijn F, Tiller M, et al. Arsenic-induced toxicity: effect on protein composition in sciatic nerve. Hum Exp Toxi- col 25: 667-674, 2006.
  14. Au WY, Tam S, Fong BM, Kwong YL. Elemental arsenic en- tered the cerebrospinal fluid during oral arsenic trioxide treat- ment of meningeal relapse of acute promyelocytic leukemia. Blood 107: 3012-3013, 2006.